Logo

Getting Closer

Jul 21, 2009

Jeremy Grushcow at The Cross-Border Biotech Blog points to the KRAS mutation genetic test to identify patients who won't respond to Erbitux or Vectibix as "exactly how personalized medicine and comparative effectiveness can interact to benefit patients, pharma companies and payors." Grushcow says payors benefit by the elimination of unnecessary prescriptions and pharma benefits as patients without the KRAS mutation are motivated to take those drugs.

Breaking News
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.